Efficacy, Safety, and Biomarkers of Neoadjuvant Bevacizumab, Radiation Therapy, and Fluorouracil in Rectal Cancer: A Multidisciplinary Phase II StudyChristopher G. Willett, Emmanuelle di Tomaso, Yves Boucher et al.|Journal of Clinical Oncology|2009Cited by 507
A Safety and Survival Analysis of Neoadjuvant Bevacizumab with Standard Chemoradiation in a Phase I/II Study Compared with Standard Chemoradiation in Locally Advanced Rectal CancerChristopher G. Willett, Dan G. Duda, Marek Ancukiewicz et al.|The Oncologist|2010Cited by 54